Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Hohmann N, Sprick MR, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A, Springfeld C. Hohmann N, et al. Clin Transl Sci. 2023 Dec;16(12):2483-2493. doi: 10.1111/cts.13661. Epub 2023 Nov 3. Clin Transl Sci. 2023. PMID: 37920921 Free PMC article.
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P. Zhou X, et al. Among authors: hohmann n. Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7. Nat Cancer. 2023. PMID: 37679568 Free PMC article.
Current published evidence on barriers and proposed strategies for genetic testing implementation in health care settings: A scoping review.
Fahim SM, Alexander CSW, Qian J, Ngorsuraches S, Hohmann NS, Lloyd KB, Reagan A, Hart L, McCormick N, Westrick SC. Fahim SM, et al. Among authors: hohmann ns. J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):998-1016. doi: 10.1016/j.japh.2023.04.022. Epub 2023 Apr 28. J Am Pharm Assoc (2003). 2023. PMID: 37119989 Review.
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
Nassar YM, Hohmann N, Michelet R, Gottwalt K, Meid AD, Burhenne J, Huisinga W, Haefeli WE, Mikus G, Kloft C. Nassar YM, et al. Among authors: hohmann n. Clin Pharmacokinet. 2022 Nov;61(11):1595-1607. doi: 10.1007/s40262-022-01175-6. Epub 2022 Oct 4. Clin Pharmacokinet. 2022. PMID: 36195807 Free PMC article. Clinical Trial.
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig A, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K. Roas M, et al. Among authors: hohmann n. Blood. 2023 Mar 2;141(9):1023-1035. doi: 10.1182/blood.2021015246. Blood. 2023. PMID: 35981498 Free article.
First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers.
Blank A, Hohmann N, Dettmer M, Manka-Stuhlik A, Mikus G, Stoll F, Stützle-Schnetz M, Thomas D, Exner E, Schmitt-Bormann B, Schaller T, Laage R, Schönborn-Kellenberger O, Arndt M, Haefeli WE, Krauss J. Blank A, et al. Among authors: hohmann n. Clin Transl Sci. 2022 Oct;15(10):2366-2377. doi: 10.1111/cts.13365. Epub 2022 Jul 23. Clin Transl Sci. 2022. PMID: 35869929 Free PMC article. Clinical Trial.
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
Walle T, Bajaj S, Kraske JA, Rösner T, Cussigh CS, Kälber KA, Müller LJ, Strobel SB, Burghaus J, Kallenberger SM, Stein-Thöringer CK, Jenzer M, Schubert A, Kahle S, Williams A, Hoyler B, Zielske L, Skatula R, Sawall S, Leber MF, Kunes RZ, Krisam J, Fremd C, Schneeweiss A, Krauss J, Apostolidis L, Berger AK, Haag GM, Zschäbitz S, Halama N, Springfeld C, Kirsten R, Hassel JC, Jäger D; NCT ANTICIPATE Investigators; Ungerechts G. Walle T, et al. Nat Cancer. 2022 Sep;3(9):1137. doi: 10.1038/s43018-022-00420-y. Nat Cancer. 2022. PMID: 35840692 Free PMC article. No abstract available.
84 results